Mandatory adjustment of RSUs and share options following recently completed rights issue

Oslo, 16 April 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 30 January 2026, regarding the final results of the rights issue raising gross proceeds of NOK 50 million (the "Rights Issue"). In accordance with the terms of the Company's agreements for Restricted share units ("RSUs") and share options ("Options"), which are an important and integral part of the Company's compensation model to attract and retain key employees and directors, the Company has today performed required RSU and Option adjustments to restitute the dilutive effect of the Rights Issue. These adjustments are made to ensure that RSU and Option holders are neither advantaged, nor disadvantaged as a result of a Rights Issue with preferential subscription rights. Accordingly, current and former members of the Board of Directors holding RSUs as of 12 January 2026, being the last date shares were traded inclusive of the right to participate in the Rights Issue, have been granted an aggregate of 3,069 additional RSUs. For further information regarding the allocation of additional RSUs to primary insiders among the board members, please see the attached notifications of trade by primary insiders. Furthermore, the exercise price for the 3,704,152 outstanding Options as of 12 January 2026 has been reduced by NOK 0.0581 per option, in accordance with the governing terms of the Option agreements and standard market practice. This adjustment has no effect on the number of Options. The exercise price for Options granted to employees in February 2026, after completion of the Rights Issue, are not affected by these adjustments. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com About Circio Building circular RNA expression systems for enhanced gene and cell therapies Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy. Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.